Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells

被引:35
作者
Muraro, M. [1 ]
Mereuta, O. M. [1 ]
Carraro, F. [1 ]
Madon, E. [1 ]
Fagioll, F. [1 ]
机构
[1] Regina Margherita Childrens Hosp, Stem Cell Transplantat & Cellular Therapy Unit, I-10126 Turin, Italy
关键词
gammadelta T cells; osteosarcoma; cytotoxicity;
D O I
10.1016/j.cellimm.2007.11.005
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Bisphosphonates have a profound effect on bone resorption and are widely used in the treatment of osteoclast-mediated bone diseases. Zoledronic acid (ZA), a third-generation biphosphonate, has a potent antitumor activity and expands gammadelta (gamma delta) T cells endowed of major histocompatibility complex-unrestricted lytic activity. Many solid tumors express tumor-specific antigens on their surface, representing targets for immune effector T cells. Nevertheless, the immune surveillance against clinically manifested tumors is relatively inefficient. Therefore, we investigated the hitherto unknown effects of ZA activated gamma delta T cells of normal donors on osteosarcoma cell lines. gamma delta T cells were stimulated with ZA and low doses of interleukin-2, and then analyzed for proliferation and generation of effector activity against osteosarcoma cell lines. Our results show the potent anti-tumor activity of ZA-stimulated gamma delta T cells and the enhanced immuno sensitivity of osteosarcoma cell lines to gamma delta T cells suggesting that osteosarcoma is another gamma delta T cell susceptible tumor type. (C) 2008 Published by Elsevier Inc.
引用
收藏
页码:63 / 72
页数:10
相关论文
共 51 条
[1]  
ANDERSON KC, 2000, AM SOC HEMATOL ED PR, V1, P147
[2]   Predictive factors for local recurrence in osteosarcoma - 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy [J].
Bacci, G ;
Ferrari, S ;
Mercuri, M ;
Bertoni, F ;
Picci, P ;
Manfrini, M ;
Gasbarrini, A ;
Forni, C ;
Cesari, M ;
Campanacci, M .
ACTA ORTHOPAEDICA SCANDINAVICA, 1998, 69 (03) :230-236
[3]   A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity [J].
Bacci, G ;
Ferrari, S ;
Tienghi, A ;
Bertoni, F ;
Mercuri, M ;
Longhi, A ;
Fiorentini, G ;
Forni, C ;
Bacchini, P ;
Rimondini, S ;
De Giorgi, U ;
Picci, P .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (01) :98-104
[4]   Autoreactivity by design: Innate B and T lymphocytes [J].
Bendelac, A ;
Bonneville, M ;
Kearney, JF .
NATURE REVIEWS IMMUNOLOGY, 2001, 1 (03) :177-186
[5]   Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro [J].
Benford, HL ;
McGowan, NWA ;
Helfrich, MH ;
Nuttall, ME ;
Rogers, MJ .
BONE, 2001, 28 (05) :465-473
[6]  
Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO
[7]  
2-0
[8]  
Body JJ, 1997, CANCER, V80, P1699, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1699::AID-CNCR23>3.3.CO
[9]  
2-A
[10]  
Boissier S, 2000, CANCER RES, V60, P2949